| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687495 | UCB INC | Methods and systems for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| US8217033 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| US9289432 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| US8809322 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
Nayzilam is owned by Ucb Inc.
Nayzilam contains Midazolam.
Nayzilam has a total of 4 drug patents out of which 0 drug patents have expired.
Nayzilam was authorised for market use on 17 May, 2019.
Nayzilam is available in spray;nasal dosage forms.
Nayzilam can be used as acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.
The generics of Nayzilam are possible to be released after 18 January, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-243) | May 17, 2026 |
| New Product(NP) | May 21, 2022 |
Drugs and Companies using MIDAZOLAM ingredient
Market Authorisation Date: 17 May, 2019
Treatment: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patie...
Dosage: SPRAY;NASAL
NAYZILAM family patents
